Keynote Financial Services LLC Buys 16,710 Shares of Pfizer Inc. (NYSE:PFE)

Keynote Financial Services LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 24.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 84,994 shares of the biopharmaceutical company’s stock after purchasing an additional 16,710 shares during the quarter. Pfizer accounts for approximately 1.7% of Keynote Financial Services LLC’s holdings, making the stock its 10th biggest position. Keynote Financial Services LLC’s holdings in Pfizer were worth $2,255,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Swedbank AB boosted its stake in shares of Pfizer by 0.7% in the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after buying an additional 37,636 shares in the last quarter. Creative Financial Designs Inc. ADV lifted its holdings in Pfizer by 9.5% in the third quarter. Creative Financial Designs Inc. ADV now owns 42,859 shares of the biopharmaceutical company’s stock valued at $1,240,000 after acquiring an additional 3,728 shares during the period. Murphy Pohlad Asset Management LLC boosted its position in shares of Pfizer by 9.5% during the 3rd quarter. Murphy Pohlad Asset Management LLC now owns 146,269 shares of the biopharmaceutical company’s stock worth $4,233,000 after purchasing an additional 12,645 shares in the last quarter. Affinity Investment Advisors LLC acquired a new position in shares of Pfizer during the 3rd quarter worth $721,000. Finally, Capital Advisors Inc. OK grew its stake in shares of Pfizer by 3.5% during the 3rd quarter. Capital Advisors Inc. OK now owns 1,439,745 shares of the biopharmaceutical company’s stock worth $41,666,000 after purchasing an additional 48,314 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

NYSE:PFE opened at $26.43 on Friday. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The firm has a market cap of $149.78 billion, a price-to-earnings ratio of 18.74, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company’s 50-day moving average is $26.35 and its two-hundred day moving average is $27.33. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the firm posted $0.10 earnings per share. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.51%. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on PFE shares. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Citigroup reduced their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. UBS Group lowered their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.